Showing posts with label SGO. Show all posts
Showing posts with label SGO. Show all posts

Wednesday, April 8, 2020

April 8, 2020 Open Mic on COVID19

Thank you to everyone who joined us tonight for our Open Mic chat on COVID-19.

We were happy to have the co-chairs of the SGO COVID-19 Task Force, gyn-oncologists Amanda Nickles Fader, MD (@amandanfader), Joshua Kesterson, MD (@KestersonJoshua), Bhavana Pothuri, MD, MS (@BPothuri) and patient advocate and Task Force member Annie Ellis (@stigetta) join us for this important discussion. 

You may find the transcript here and the analytics here.

We covered a number of different areas related to COVID-19 and the gyn cancer patient experience. 

Concerns and Difficulties  

  • I’m having a really hard time deciding whether to go for my next blood test and then infusion during COVID-19 risk. I skipped one infusion already
  • I am concerned about surgery delays in light of COVID 19
  • Every surgical procedure potentially exposes the patient and a dozen HCW to #COVID19. #PPE is still an issue in many places. And access to testing has been an issue as well.
  • Not too bad since doing chemo gave a taste of isolation. But i miss going outside to stay active 
  • Many lynch syndrome patients get annual tests, especially colonoscopies, so having them put off by even a few months can be stressful 
  • The human connection is so important and what I love about caring for patients. With social distancing, it is challenging. 


SGO Task Force - Guidelines and Care

  • @SGO_org COVID-19 Task Force has been working around the clock to develop strategies for doctors to continue to provide the very best care possible to their patients during these difficult times 
  • Goal is to keep patients safe and in this current crisis, that involves avoiding an infection with no cure. SGO COVID 19 Task Force developing guidelines so no patients left behind/forgotten.
  • The SGO COVID-19 Task Force guidelines are specific for GYN cancers. https://www.sgo.org/clinical-practice/management/covid-19-resources-for-health-care-practitioners/
  • Hang in there! Cancer care is still being prioritized, but changes are being made to minimize patients' risk of exposure - especially important as we recognize that cancer patients may be at high risk for becoming quite ill from COVID-19. 
  • Please understand that you all are very important and we are making the best decisions we can during this time of greater infection risk and increased resource limitations. Thank-you for your patience and understanding #COVID19 #GYNcsm #SGOCOVID19


Treatment / Follow-up Care

  • Depends on how you are feeling and what your treating #MD thinks whether risks are greater than benefit; These are hard decisions and need to be individualized.
  • I think the issue is that we don't know how long this is going to last - and we certainly want to keep you on track for your treatment. It's a difficult decision 
  • Agree they can be stressful, but know it is more risky to come in now for a screening test.
  • Delays in cancer screening and health check ups should only be temporary. Trying to balance risks of medical care with exposures to COVID-19. 
  • Yes in high #COVID burden areas this is the case. But even in these areas we are able to do cases that we deem are necessary. Working hard to maintain care so it does not impact outcomes. 

Telemedicine

  • But telemedicine allow us to keep very close tabs and communicate regularly with our cancer survivors. 
  • Agree, @temkins. Telemedicine is a great alternative to deliver care for our patients and cancer survivors. 
  • Something good has to come out of the COVID crisis and telemedicine and the improved patient access and convenience is going to be one of those positives.
  • Hope we will also see sustainable improvement in accessibility of second opinions with reimbursement for televisits. 
  • Telemedicine is one option but there are different laws/regulations across states 
  • This is important! We are limited in #telehealth by regulations - we need legislators to learn from this issue and expand our ability to provide care across state lines 
  • Language differences are also a challenge; interpreting clinic appointments is often challenging baseline, still need to find more #equitable solutions in order for telemedicine to not create/increase disparities imo 

Disparities

  • As we hear more about the rates of infection/deaths of African Americans with COVID19, I worry we will continue to be excluded from clinical trials due to existing comorbidities.
  • #clinicaltrials are the key to innovation in oncology and enrolling a representative patient population is good science. 
  • I hope this COVID crisis draws attention to the disparities in outcomes for African-Americans as well as based on economic status, geographic location, etc. and serves as a call for equality for all
  • In light of the high mortality rates, the financial health disparities will also become a factor as they will be faced with paying for costs of burial for those without insurance.
  • And no, we shouldn’t wait to address this when it’s all over, as some suggest. We should tackle it now. We should recognize there are certain communities that are in greater need for resources, testing, access now. Should not accept these worse outcomes are inevitable. 

Genetics Counselors

  • Genetic counselors across U.S. have been shifting our clinics to telephone/video & finding creative work-arounds to help patients access recommended genetic testing; we're doing our best to keep everyone safe, but missing in-person support of patients & families 


Support 


Survey 

Patient survey: Any person w/ #ovariancancer #fallopiancancer or #peritonealcancer is invited to complete this survey from research advocate @Stigetta on survivors' experiences during the COVID-19 pandemic. https://www.surveymonkey.com/r/OvcaCV19



Additional resources shared during the chat may be found at the end of this blog. 

Save the date for our next #gyncsm chat: 
Wed May 13, 2020 9pmET .
Topic: Side effects of Surgery

We'll end this blog with Tweets from two participants. 

I want to give the biggest of thanks to all the health care providers and medical staff. You guys are amazing each and every day! In Irish, thank you is “go raibh maith agat” which means “may you have goodness” I wish all the goodness for you! ❤️ 

Please spread the word to stay home to #flattenthecurve #GYNcsm #SGOCOVID19

Wishing wellness and safety for all,

Dee and Christina 


OTHER RESOURCES SHARED:
Covid19 resources for gyn cancer patients: Foundation for Women’s Cancer @GYNcancer
https://www.foundationforwomenscancer.org/news-stories/covid-19/
https://www.foundationforwomenscancer.org/covid-19-helpful-resources/

Questions? Comments? Concerns? for @SGO_org & @GYNCancer? You can leave a post FWC’s Facebook page! https://www.facebook.com/foundationforwomenscancer/

The @SGO_org website is a great resource for #COVID19 
https://www.sgo.org/clinical-practice/management/covid-19-resources-for-health-care-practitioners/ 

Covid19 webinars this week for cancer patients
Join @CancerAdvocacy Thursday, April 9, Noon ET: https://register.gotowebinar.com/register/3253972083140234252 
Join @SHAREing and @GYNCancer on Friday, April 10 at 2pm ET https://register.gotowebinar.com/register/8945691880708190222 #gyncsm

@DrMarkham- What People With Cancer Need to Know
https://www.cancer.net/blog/2020-04/coronavirus-and-covid-19-what-people-with-cancer-need-know on @CancerDotNet

@SHAREing COVID-19 Updates for Gynecologic Cancer Patients
https://www.youtube.com/watch?v=5z4umo0VYLc&feature=youtu.be

@FacingOurRisk has put out some great resources: 
Coping with Hereditary Cancer During the COVID-19 Pandemic
https://www.facingourrisk.org/about-us/about/covid-19.php 
A second helping of stress: Coping with hereditary cancer during the COVID-19 pandemic - register to view https://register.gotowebinar.com/recording/4410816644974202125 

@CancerAdvocacy Coronavirus and Cancer Resources for Survivors 
https://www.canceradvocacy.org/blog/coronavirus-cancer-resources-for-survivors/?mc_cid=d94d24cb7d&mc_eid=14aaa5ca15 

How long is it safe to delay gynecologic cancer surgery? By @RobinsonRossiGO 
https://www.mdedge.com/chestphysician/article/219514/coronavirus-updates/how-long-it-safe-delay-gynecologic-cancer-surgery/page/0/1 

Practicing self-care during the Time of Coronavirus @JBBC for @power4patients
 https://powerfulpatients.org/2020/03/24/practicing-self-care-in-the-time-of-coronavirus-how-to-mind-your-mental-health-and-well-being-during-covid-19/ #gyncsm #patientchat

Livestrong @livestrong Tips and Tools for living with Cancer during Covid-19 
https://blog.livestrong.org/tips-tools-for-living-with-cancer-during-covid-19-7c1ac49ea260?gi=f945388c302f

International Gynecologic Cancer Society @IGCSociety 
https://igcs.org/covid-19/

Here's what the FDA has to say so far re: clinical trials during COVID 19 
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-pandemic?utm_source=&utm_medium=&utm_campaign= 

For AYA’s, check out @ElephantsTea ‘s #COVID19 resource page https://www.elephantsandtea.com/covid-19/
I love @DansHouseofHope, @LacunaLoft, and @MDAndersonNews Cancer 180 program also for additional resources! 

@CancerDotNet Coronovirus info
https://www.cancer.net/blog/tags/coronavirus

OCRA Covid19 info for ovarian cancer patients
 https://ocrahope.org/patients/information-on-covid-19-for-ovarian-cancer-patients/



Wednesday, April 11, 2018

SGO Annual Meeting Research Review and Ask the Doc April 2018

Twenty-four participants shared what they had learned at the SGO Annual Meeting or asked questions about research presented at the meeting during this month's #gyncsm chat. You may find more analytics here. You may find a transcript from the chat here.

We covered a number of different research areas from treatments to survivorship to funding for research.

T1: What were the results of the study comparing minimally invasive surgery (MIS) w/ radical hysterectomy in early cervical cancer. Will the results change practice?

  • "Disease-free survival following minimally invasive procedures significantly lagged behind radical hysterectomies done by open laparotomy," -Pedro T. Ramirez, MD. I found this fascinating.
    • some suggested uterine manipulator use (not assessed in the study), also discussed immature data, early stopping.
    • Any reasons would be speculation. But I think we get bigger tissue margins with open surgery
    • data safety monitoring committee (filled with GYN ONCS) said the study should be stopped
T2: Several studies used targeted therapies to treat #ovariancancer - Which results stood out for you? Were side effects critical in any of the studies?
  • The #PARPi combinations are very exciting - responses and improved outcomes regardless of #BRCA status are encouraging
  • From our Scientific Director, Dr. Deb Zajchowski, “Exciting preliminary results for PARP inhibitors combined with immune checkpoint inhibitors — particularly in platinum-resistant patients.” (@ClearityFnd) 
T3: Which studies presented at the meeting will impact treatment of women with #endometrialcancer #uterinecancer #sarcoma?

  • The combo of everolimus & letrozole was quite successful in #endometrialcancer - this is the 2nd study to demonstrate this
  • Excited re our study (in rodents) of everolimus-eluting IUD pres by @JDottinoMD - could allow pts to avoid surgery in endo ca


  • My friend Matt Anderson, MD, PhD, presented on the genomic profiling of #uterine #leiomyosarcoma from The Cancer Genome Atlas as well as his own lab in Baylor. Data from @ALazarMDPhD was included. This is bigly important for us
  • I was not at SGO but results from the phase 2 trial looking at carbo/taxol vs carbo/tax + trastuzimab (herceptin) in uterine serous CA with Her2/neu overexpression were presented. Improved PFS w/addition of herceptin.
    • Agree... exciting abstract. Several pre-analytical issues that can affect Her2 testing results which will be important to consider for the future
T4: What research on palliative care and survivorship do you think will impact patients lives the most - or that survivors should ask their gyn/onc's about?

  • There was a study that finally measured and estimated rates of post op lymphedema which were much higher than anticipated. If we can measure it we can look for ways to reduce it. 
  •  Overall, I think it has been great to see an increase each year in survivorship studies and talk of long-term care planning and navigators/coordinators. Patients living longer and more emphasis on support.
T5: Once again studies showed less gyn cancer clinical trials and lower funding for gyn cancer research. What suggestions were made to increase enrollment and funding?
  • We MUST advocate for gynecologic cancer funding - write your Congressman and tell them that this funding must be INCREASED!!
  • the photo in this tweet shows how great the need is via @ShannonWestin
  • Outcomes are better for minorities who have access to #clinicaltrials - we need funding to ensure these trials are available 
    • I thought this was an important study. #clinicaltrials are an important part of cancer care. Many in general population still think trials are last resort and consider them "experimental" in a very negative risky way.
  • From our Scientific Director, Dr. Deb Zajchowski, “We need more funding. We also need to get the word out to enroll in the many clinical trials that are already available. There are more than 300 #clinicaltrials that #ovariancancer patients can enter.”
We have several questions/thoughts out there - feel free to now add any additional tweets re: the latest gynecologic cancer research.
  • Here is a link to a study reported at SGO on a vaccine to prevent recurrence in OC https://t.co/phQx2osDcN
  • Can you please tell us a little more about check point inhibitors and what that they’re used for in regards to #Lynchsyndrome cancers
    • Right now - they are FDA approved for any tumor that has MSI (microsatellite instability) - that includes Lynch Syndrome assoc tumors
    • Essentially the MMR in LS makes the cells more susceptible to attack by the immune cells. The checkpoint inhibitors allow the immune system to be more effective.
  • Still on #uterine #leiomyosarcoma: I'm glad the #sarcoma med oncs talked about the many lines of chemo -- I can think of at least 6 -- they might give. Some gyn oncs offer fewer
  • I was very surprised that chemo for early stage endometrial Cancer didn’t improve outcomes. Especially after last years ASCO when it was discussed that it may replace radiation.
  • Great video to share (from SGO) on clinical trial basics! https://t.co/UWjBqxQ584
  • There was a study that finally measured and estimated rates of post op lymphedema which were much higher than anticipate…
Additional resources mentioned during the chat may be found below. 

Patients and caregivers are invited to continue our discussion on the Smart Patients platform at  https://www.smartpatients.com/partners/gyncsm

Join us next month on Wednesday May 9,2018 at 9pm ET for our chat on Palliative Care - When and Why? with guest Christian Sinclair @ctsinclair (#hpm). 

See you then, 

Dee
#gyncsm Co-founder


Resources:


Friday, April 6, 2018

April 11, 2018 Chat - SGO Annual Meeting Research Review and Ask the Doc



Part of our mission as a community for those impacted by gynecologic cancers is to inform and educate our followers regarding new developments in disease screening, treatment and survivorship.

A number of those developments were presented as research studies and practice innovations during the SGO Annual Meeting in New Orleans in March. This 49th Annual Meeting drew over 2500 participants including gynecologic oncologists, oncologists, radiologists, genetic counselors, oncology nurses and patient advocates. The #gyncsm community will discuss research projects and trial results presented at this meeting during our monthly chat on April 11, 2018 at 9pm ET (8pm CT, 6pm PT).

Join us as we cover a variety of research topics including answering questions such as:

What is the impact minimally invasive surgery has had on survival of women diagnosed with early stage cervical cancer? 

What is the latest news on the use of targeted therapies (niraparib, pemrolizumab, Olaparib, durvalumab) in treating ovarian cancer?


What impact could Phase I trial of Vigil® vaccine personalized engineered autologous tumor cells (EATC) have on preventing recurrence in women with ovarian cancer ?

What is the role of palliative care and lay navigators in treating and supporting gyn cancer survivors ?

What is the impact of chemotherapy and radiotherapy on endometrial cancer survival? 

How can we improve funding for gyn cancer research?

What is the impact of participation in clinical trials on minority patients? 

During the chat we will open the discussion to questions participants have for our health care professionals.

Check the SGO Facebook page (https://www.facebook.com/SGO.org/), their Twitter account (@SGO_org and #SGOmtg), or their website (https://www.sgo.org/education/annual-meeting-on-womens-cancer/annual-meeting-media-coverage-3/) for more meeting coverage and potential topics of interest.

We look forward to having you join us.

Dee
#gyncsm co-moderator

Friday, April 7, 2017

April 12th Chat: SGO Annual Meeting Research Review and ASK the Docs



This month's #gyncsm chat, on April 12th at 9:00pm EST, will focus on research news from the 2017 SGO Annual Meeting on Women's Cancer including a segment we call ASK the DOC. 

The SGO (Society of Gynecologic Oncology) Annual Meeting on Women's Cancer (#SGOmtgwas held in National Harbor, MD on March 12th to the 15th. You may access the meeting agenda, speakers and presentations by visiting:
https://sgo.confex.com/sgo/2017/meetingapp.cgi/Home/0

We will begin our chat on Wednesday by discussing research results reported at this year's annual meeting and then have participants "ask our Docs" questions. 

These questions will guide our chat: 


T1: What #SGOMtg presentations did you personally find of most interest? Also, what were some of the "hot topics" of discussion?

T2: Which #SGOMtg studies do you think will most interest patients? Were there findings survivors need to take immediate note of? 

T3: What was the #Trials4GynCancerNow campaign which took part during the #SGOMtg? How does gyn cancer trial access impact care? 

T4: What was something you learned or were reminded of during #SGOMtg that you plan to implement or follow-up on? 

T5: For our last topic, we'll let our participants ask questions they have about gynecologic cancer research.


If you would like a preview of some of the research presented at the meeting, please read this excellent report on Highlights from the 2017 Annual Meeting on Women's Cancer by research advocate, Annie Ellis (@Stigetta) or visit the Cure Magazine Conference page for eleven articles discussing research presented at the meeting. Or view the Foundation for Womens Cancer video below. 





See you on the 12th!

Dee
Co-moderator #gyncsm 

Sunday, March 12, 2017

Advocating for Gynecologic Oncology Clinical Trials - #Trials4GynCancerNow

The SGO (Society of Gynecologic Oncology) is conducting their Annual Meeting March 12-15, 2017. You can follow research presented at the meeting by following the hashtag #SGOMtg on Twitter. Note that we'll discuss SGO Meeting highlights during our April 12th #gyncsm chat

During their annual meeting, SGO will be conducting a social media campaign to advocate for gynecologic cancer clinical trials. #gynscm is please to support this campaign and we hope you will join us.

There has been a steep decline in the number of clinical trials in gynecologic cancer since the restructuring of the NCI-sponsored cooperative groups in 2012.  Information about the campaign can be found in this SGO document.

You can join us as we support this campaign by tweeting the following starting on Monday, March 13th at 9:35amEST:
Women with #gyncancer deserve progress. Fund trials now @realDonaldTrump #Trials4GynCancerNow @SGO_org

Feel free to send additional tweets using #Trials4GynCancerNow to encourage increased funding of NCI trials. 

Thanks, 

Dee
#gyncsm Co-Founder 

Wednesday, June 8, 2016

June 8, 2016: What's New in Gyn Cancer Research

Thirty-four #gyncsm community members chatted about What's New in Gyn Cancer Research.  Our discussion focused on research presented at the Society of Gynecologic Oncology Annual Meeting (#SGOmtg) held March 19-22 in San Diego, the American Association for Cancer Research Annual Meeting (#AACR16) held April 16-20 in New Orleans, and the American Society of Clinical Oncology Annual Meeting (#ASCO16) held June 3-7 in Chicago.

You may find the transcript here and the chat analytics here

We began our chat by remembering our friend and supporter of #gyncsm, Jody Schoger, #bcsm co-founder. She was an amazing advocate. 

Topic Questions / Sample Response Tweets: 

T1:Do you research new treatments and studies online? Do you follow scientific meetings like #SGOmtg, #AACR16 and #ASCO16? 

  • I participate in twitter to inform patients and families of key findings from meetings using #SGOMtg #ASCO16 #AACR16
  • A caution in keeping up with research is how long it can take for studies to lead to any change in practice guidelines
  • Plus I want to be prepared with what options I will have if I recur again
  • I find @ASCOPost emails useful.

T2:GOG 252 did not support a previous study which showed IP chemo benefit (tough treatment for many). How does this change things? 
  • #ASCO16 session on GOG252 Walker: Median PFS all three arms GOG252 similar
  • There is still a benefit for IP chemo - demonstrated in 3 large randomized trials We need to understand who benefits most
  • Yes, Dr Gourley mentioned 3 Pos studies(GOG 104,114,172), 1 neg(252)
  • I feel more confident telling patients that if they want the benefits of GOG172, we have to at least try the same regimen 
  • #ASCO16 session on GOG252 Mackay-“unresolved issues” 
T3:In the hot topics of immunotherapy, precision medicine, and genetics, which #SGOmtg/ #AACR16/ #ASCO16 research excited you? 
  • https://t.co/DfjMW5ZPwP adv endometrial cancer : everolimus, letrozole,metformin showed clinical benefit in ph 2study 
  • I'm very excited about the interest & research on hereditary cancers and how to use this to guide targeted therapy-new options! 
  • Pembrolizumab:well tolerated, showed antitumor activity pts w/ PD-L1+ adv cervical squamous cell cancer.https://t.co/P5KsDdtTUA
  • Precision medicine for Gyn disease is finally taking root. It not only bevucizumab anymore
  • Kurian: Genes mutations in #ovca article https://t.co/O1mgn5zqoc
  •  Liquid biopsies (look for circulating tumor DNA in blood) https://t.co/PUROem0e7N 4 screening and during treatment talked about 
  • There was a clear theme of trying to find out who are the responders to a given Rx - understanding the pts that benefit the most
T4: What studies reported at #ASCO16 in palliative care, survivorship, and psychosocial research could help gyn cancer survivors? 
  • The data on early involvement of palliative care should be able to be extrapolated to gyn cancer patients and caregivers
  • QOL may predict survival in recurrent #ovca @ASCOpost -https://t.co/te0NvFAkPJ 
  • Real studies on improving chemo induced. Neuropathy with PT
  • Qol: older long term #ovca survivors better QOL than younger https://t.co/OGKtr3t0oi
  • It was great to see presentations beyond standard chemo treatment. ASCO. It's not just about chemo
T5: As "patient-centered" research becomes more accepted, what do you see as the role of the patient in future cancer research?
  • Been great to see White House precision medicine efforts. workshop this week: Engaging participants as partners in research
  • Let's start with adding quality of life components to all studies.
  • Being more patient-centered means looking beyond overall survival endpoints. Also need patients in design of studies to reach.
  • This from #SGOmtg patient-centered research: Accepting treatment w/ Side Effects change as Goals Change https://t.co/xhY9Wg1FRn
  • Patients see so much in the practical side of clinical trials that trial designers don't think about.
  • I would love to see advocates on irb. And involved in trial design

Our next #gyncsm chat is on  Wednesday  July13th  at 9pmET when we will discuss Spirituality and Quality of Life with guest @MeredithGould of #hlthsp. We hope you can join us. 

Remember patients and caregivers are invited to continue our discussion on the Smart Patients platform at https://t.co/dFCf1Mcahw

See you next month!

Dee Sparacio
Co-founder #gyncsm Community and Chat

Resources:
@SGO_org Society of Gynecologic Oncology: #SGOmtg Abstracts and Late-breaking Abstracts https://t.co/vjzYlqOTC1

@AACR American Association for Cancer Research: #AACR16 Abstracts https://t.co/2sZ6G7QveL

@ASCO American Society of Clinical Oncology: #ASCO16 abstracts https://t.co/3vruaogIUV

"Roundup of #OvarianCancer Abstracts From #SGOmtg on Women’s Cancer" https://t.co/7z5UlcDx17 via @ascopost

@ocrfa statement on GOG 252 https://t.co/XTjyzfOpw9

key abstracts at #ASCO16 Gyn Onc at ASCO 2016: Ovarian Cancer https://t.co/t1krzp6ymx via @YouTube

Abstracts #ASCO16 Gyn Onc at ASCO 2016: Cervical Cancer https://t.co/780LCAOh72 via @YouTube

abstract review from #ASCO16 - Gyn Onc at ASCO 2016: Endometrial Cancer https://t.co/Dsh7AdyArv via @YouTube

exercise and neuropathy: https://t.co/LZwUSbWVAi

Engaging participants as partners in research - Workshop Storify https://t.co/RrRVpndnQd via @stanfordmedx

researchers going directly to metastatic breast cancer patients. https://t.co/iV2dnxfzIY?


Friday, June 3, 2016

What's New in Gyn Cancer Research - June 8th #gyncsm Chat




Join us on June 8, 2016 at 9pm ET (8pm CT/6pm PT) as the #gyncsm community discusses What's New in Gyn Cancer Research. 

Our chat will focus on research presented at the Society of Gynecologic Oncology Annual Meeting (#SGOmtg) held March 19-22 in San Diego, the American Association for Cancer Research Annual Meeting (#AACR16) held April 16-20 in New Orleans, and the American Society of Clinical Oncology Annual Meeting (#ASCO16) held June 3-7 in Chicago.

We hope you will join us as we answer these questions:

T1: Do you research new treatments and studies online? Do you follow scientific meetings like #SGOmtg, #AACR16 and #ASCO16? 

T2: GOG 252 did not support a previous study which showed IP chemo benefit (tough treatment for many). How does this change things? 

T3: In the hot topics of immunotherapy, precision medicine, and genetics, which #SGOmtg/ #AACR16/ #ASCO16 research excited you? 

T4: What studies reported at #ASCO16 in palliative care, survivorship, and psychosocial research could help gyn cancer survivors? 

T5: As "patient-centered" research becomes more accepted, what do you see as the role of the patient in future cancer research?

You can search abstracts and sessions from each meeting on these corresponding pages:

#SGOmtg Abstracts & Late-breaking Abstracts
 https://www.sgo.org/2016-annual-meeting-archives/

#AACR16 Abstracts
 http://www.abstractsonline.com/plan/start.aspx

#ASCO16 Abstracts
 http://abstracts.asco.org/176/CatView_176_B.html


Do you have a research topic you are interested in learning more about? Let us know by commenting below.

See you on the 8th.

Dee
Co-founder #gyncsm